BACKGROUND: Imatinib is the current standard frontline therapy for chronic myelogenous
leukemia (CML). In the majority of patients, imatinib induces a complete cytogenetic …

Chronic myelogenous leukemia (CML) presents a unique opportunity to develop therapeutic
strategies using vaccination against a truly tumor-specific antigen that is also the oncogenic …

Previous clinical vaccination trials of BCR-ABL peptides demonstrated that certain amino-
acid sequences crossing the p210 breakpoint were immunogenic in patients with chronic …

Background Although imatinib is the standard treatment for chronic myeloid leukaemia, not
all patients reach complete cytogenetic remission (CCR) and most maintain detectable …

A tumor-specific, bcr-abl-derived fusion peptide vaccine can be safely administered to
patients with chronic myelogenous leukemia (CML) and can elicit a bcr-abl peptide-specific …

Peptides from the e14a2 BCR-ABL junction will elicit T-cell responses in vitro. Here, 19
imatinib treated CML patients in first chronic phase were vaccinated with BCR-ABL peptides …

BACKGROUND AND OBJECTIVES: Chronic myelogenous leukemia (CML) presents a
unique opportunity to develop therapeutic strategies using vaccination against a truly tumor …

Purpose: Chronic myeloid leukemia (CML) can be responsive to T-cell–mediated immunity.
K562/granulocyte macrophage-colony stimulating factor (GM-CSF) is a GM-CSF producing …

Abstract Background. A 63-year-old woman with chronic myeloid leukemia (CML) received
treatment with interferon (IFN)-α for 6 years. After achieving a complete cytogenetic …

The development of cancer vaccines directed against myeloid leukaemias has been a
research area of intense interest in the past decade. Both human studies in vitro and mouse …